Lack of MIR-133a decreases contractility of diabetic hearts: A role for novel cross talk between tyrosine aminotransferase and tyrosine hydroxylase

Diabetes

Volumn 65, Issue 10, 2016, Pages 3075-3090

  Nandi, Shyam Sundar ^a   Zheng, Hong ^a   Sharma, Neeru M ^a   Shahshahan, Hamid R ^a   Patel, Kaushik P ^a   Mishra, Paras K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; MICRORNA 133A; MICRORNA 133A MIMIC; MICROTUBULE ASSOCIATED PROTEIN 2; MYOSIN HEAVY CHAIN BETA; NORADRENALIN; PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SERCA 2A PROTEIN; SMALL INTERFERING RNA; STREPTOZOCIN; TYROSINE 3 MONOOXYGENASE; TYROSINE AMINOTRANSFERASE; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR; MIRN133 MICRORNA, RAT;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HEART CONTRACTION; HEK293 CELL LINE; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; HEK293 CELLS; HEMODYNAMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE, TRANSGENIC; MICRORNAS; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TYROSINE 3-MONOOXYGENASE; TYROSINE TRANSAMINASE;

EID: 84989159437     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-0023     Document Type: Article

References (51)

1. Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009;13:778-789
2. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013;113:676-689
3. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007;8:166
4. Tang X, Gal J, Zhuang X, Wang W, Zhu H, Tang G. A simple array platform for microRNA analysis and its application in mouse tissues. RNA 2007;13:1803-1822
5. Mishra PK. Is miR-133a a promising therapeutic target for heart failure? J Diabetes Metab 2014;5:e118
6. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-618
7. Nandi SS, Duryee MJ, Shahshahan HR, Thiele GM, Anderson DR, Mishra PK. Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading. Am J Transl Res 2015;7:683-696
8. Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW 2nd, Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 2014;18:415-421
9. Chavali V, Tyagi SC, Mishra PK. Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes 2013;6:151-160
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431
11. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053
12. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res 2011;157:253-264
13. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602
14. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213-3223
15. Williams RS, Schaible TF, Scheuer J, Kennedy R. Effects of experimental diabetes on adrenergic and cholinergic receptors of rat myocardium. Diabetes 1983;32:881-886
16. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-690
17. Wallukat G. The beta-adrenergic receptors. Herz 2002;27:683-690
18. Belke DD, Swanson EA, Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 2004;53:3201-3208
19. Dinçer UD, Güner S, Tay A, et al. Decreased expression of beta1- and beta2-adrenoceptors in human diabetic atrial appendage. Cardiovasc Diabetol 2003;2:6
20. Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 2007;137(Suppl. 1):1539S-1547S; discussion 1548S
21. Thackeray JT, Beanlands RS, Dasilva JN. Altered sympathetic nervous system signaling in the diabetic heart: Emerging targets for molecular imaging. Am J Nucl Med Mol Imaging 2012;2:314-334
22. Ganguly PK, Dhalla KS, Innes IR, Beamish RE, Dhalla NS. Altered norepinephrine turnover and metabolism in diabetic cardiomyopathy. Circ Res 1986;59: 684-693
23. Chon KH, Yang B, Posada-Quintero HF, et al. A novel quantitative method for diabetic cardiac autonomic neuropathy assessment in type 1 diabetic mice. J Diabetes Sci Technol 2014;8:1157-1167
24. Mehere P, Han Q, Lemkul JA, et al. Tyrosine aminotransferase: Biochemical and structural properties and molecular dynamics simulations. Protein Cell 2010; 1:1023-1032
25. Chesnokov VN, Gadzhiev VG, Leontyeva GI, Zelenin SM, Mertvetsov NP. Hydrocortisone regulation and expression of tyrosine aminotransferase gene in various tissues of rat. Biomed Biochim Acta 1990;49:1177-1186
26. Sloan EK, Tarara RP, Capitanio JP, Cole SW. Enhanced replication of simian immunodeficiency virus adjacent to catecholaminergic varicosities in primate lymph nodes. J Virol 2006;80:4326-4335
27. Castaldi A, Zaglia T, Di Mauro V, et al. MicroRNA-133 modulates the b1-adrenergic receptor transduction cascade. Circ Res 2014;115:273-283
28. Chavali V, Tyagi SC, Mishra PK. Differential expression of dicer, miRNAs, and inflammatory markers in diabetic Ins2+/- Akita hearts. Cell Biochem Biophys 2014;68:25-35
29. Horie T, Ono K, Nishi H, et al. MicroRNA-133 regulates the expression of GLUT4 by targeting KLF15 and is involved in metabolic control in cardiac myocytes. Biochem Biophys Res Commun 2009;389:315-320
30. Feng B, Chen S, George B, Feng Q, Chakrabarti S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 2010;26:40-49
31. Pool PE, Covell JW, Levitt M, Gibb J, Braunwald E. Reduction of cardiac tyrosine hydroxylase activity in experimental congestive heart failure. Its role in the depletion of cardiac norepinephrine stores. Circ Res 1967;20:349-353
32. Funahashi H, Izawa H, Hirashiki A, et al. Altered microRNA expression associated with reduced catecholamine sensitivity in patients with chronic heart failure. J Cardiol 2011;57:338-344
33. Daly PA, Sole MJ. Myocardial catecholamines and the pathophysiology of heart failure. Circulation 1990;82(Suppl.):I35-I43
34. Ganguly PK, Beamish RE, Dhalla KS, Innes IR, Dhalla NS. Norepinephrine storage, distribution, and release in diabetic cardiomyopathy. Am J Physiol 1987; 252:E734-E739
35. Cai WF, Liu GS, Lam CK, et al. Up-regulation of micro-RNA765 in human failing hearts is associated with post-transcriptional regulation of protein phosphatase inhibitor-1 and depressed contractility. Eur J Heart Fail 2015;17:782-793
36. Wahlquist C, Jeong D, Rojas-Muñoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508:531-535
37. Ning B, Qi X, Li Y, Liu H, Zhang F, Qin C. Biventricular pacing cardiac contractility modulation improves cardiac contractile function via upregulating SERCA2 and miR-133 in a rabbit model of congestive heart failure. Cell Physiol Biochem 2014;33:1389-1399
38. Zarain-Herzberg A, García-Rivas G, Estrada-Avilés R. Regulation of SERCA pumps expression in diabetes. Cell Calcium 2014;56:302-310
39. Aurora AB, Mahmoud AI, Luo X, Johnson BA, et al. MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+overload and cell death. J Clin Invest 2012;122:1222-1232
40. Hua Y, Zhang Y, Ren J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: Role of microRNA-1 and microRNA-133a. J Cell Mol Med 2012;16:83-95
41. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008;22:3242-3254
42. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010;106:166-175
43. Fushimi H, Inoue T, Matsuyama Y, et al. Impaired catecholamine secretion as a cause of diabetic autonomic neuropathy. Diabetes Res Clin Pract 1988;4:303-307
44. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621
45. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang CS. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 1993;88:1299-1309
46. Sharma P, Hingorani A, Jia H, et al. Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. Hypertension 1998;32: 676-682
47. Webster GJ, Petch EW, Cowen T. Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxytryptamine specific to mesenteric perivascular sympathetic nerves and without loss of nerve fibers. Exp Neurol 1991;113:53-62
48. Bonkowsky HL, Collins A, Doherty JM, Tschudy DP. The glucose effect in rat liver: Studies of delta-aminolevulinate synthase and tyrosine aminotransferase. Biochim Biophys Acta 1973;320:561-575
49. Chesnokov VN, Gadzhiev VG, Tevs NR, Zelenin SM, Leont'eva GI, Mertvetsov NP. Tissue-specific hormonal regulation of the level of tyrosine aminotransferase mRNA in rats. Biokhimiia 1990;55:59-64 [in Russian]
50. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-1146
51. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012;110:496-507